p38 inhibitors: Beyond pyridinylimidazoles

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 7, 2005, Pages 801-816

  Dominguez, Celia ^a   Tamayo, Nuria ^b   Zhang, Dawei ^b  

^a AMGEN INC   (United States)

^b NONE

Author keywords

Cytokine biosynthesis inhibitor; Cytokine mediated disease; IL 1 ; Inflammation; p38 kinase inhibitor; p38 mitogen activated protein kinase (MAPK); TNF

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; BENZAMIDE DERIVATIVE; BENZOPHENONE DERIVATIVE; CYTOKINE; DORAMAPIMOD; EO 1428; EO 1606; IMIDAZOLE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; RO 3201195; SB 242235; SCIO 469; SX 011; TRIAZINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VX 702;

BINDING KINETICS; CLINICAL TRIAL; CROHN DISEASE; CRYSTALLOGRAPHY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG WITHDRAWAL; HUMAN; MEDICAL LITERATURE; META ANALYSIS; MOLECULAR MODEL; NEUROLOGIC DISEASE; PATENT; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; TOOTH PAIN;

EID: 22744454243     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.7.801     Document Type: Review

References (41)

1. FOSTER ML, HALLEY F, SOUNESS JE: Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect. (2000) 13:488-497.
2. RUTGEERTS P, D'HAENS G, TARGAN S et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 117:761-769.
3. MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann. Intern. Med. (1999) 130:478-486.
4. ELLIOT MJ, MAINI RN, FELDMANN M et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105-1110.
5. VAN DE PUTTE LB, RAU R, BREEDVELD FC et al.: Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis. Arthritis Rheum. (1999) 42:S400.
6. COHEN SB: WOOLLEY JM, CHAN WW: Interleukin 1 receptor antagonist Anakinra improves functional status in patients with rheumatoid arthritis. J. Rheumatol. (2003) 30:225-231.
7. LEONARDI CL, POWERS JL, MATHESON RE et al.: Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. (2003) 349:2014-2022.
8. GOTTLIEB AB, EVANS R, LI S et al.: Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. (2004) 51:534-542.
9. PAUL A, WILSON S, BELHAM CM et al.: Stress activated protein kinases: activation, regulation and function. Cell. Signal. (1997) 9:403-410.
10. NEWTON R, HOLDEN N: Inhibitors of p38 mitogen activated protein kinase potential as anti-inflammatory agents in asthma? Biodrugs (2003) 17:113-129.
11. HAN J, LEE JD, JIANG Y, LI Z, FENG L, ULEVITCH RJ: Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J. Biol. Chem. (1996) 271:2886-2891.
12. LEE JC, LAYDON JT, McDONNELL PC et al.: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1994) 372:739-746.
13. VERTEX USA: Vertex has suspended development of VX 745, a p38 MAP kinase inhibitor, which was in Phase II trials in the: USA and Europe as potential treatment for rheumatoid arthritis. Vertex Inc, Press release (September 2001).
14. SmithKline Beechman (now GlaxoSmithKline) has discontinued development of SB 242235, a cytokine suppressor (SmithKline Beechman, April 1999). This product was in Phase I clinical studies in the UK (SmithKline Beechman, March 1999) and was being investigated as a potential treatment for rheumatoid arthritis (SmithKline Beechman, April 1999) R&D Focus Report March 27 2001.
15. BOEHM JC, ADAMS JL: New inhibitors of p38 kinase. Expert Opin. Ther. Patents (2000) 10:25-37.
16. JACKSON PF, BULLINGTON JL: Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem. (2002) 2:1011-1020.
17. ADAMS JL, BOEHM JC, KASSIS S et al.: Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett. (1998) 8:3111-3118.
18. ADAMS JL, BOEHM JC, GALLAGHER TF et al.: Pyrimidinyimidazole inhibitors of p38: cyclic N-imidazole subsdtuents enhance p38 kinase inhibition and oral activity: Bioorg. Med. Chem. Lett. (2001) 11:2867-2870.
19. FULLERTON T, SHARMA A, PRABHAKAR U et al.: Suppression of ex vivo cytokine production by SB-242235, a selective inhibitor of p38 MAP kinase. Clin. Pharmacol. Ther. (2000) 67:114.
20. REVESZ L, BLUM E, DIPADOVA FE et al.: Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis. Bioorg. Med. Chem. Lett. (2004) 14:3595-3599.
21. REVESZ L, DIPADOVA FE, BUHL T et al.: SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:1261-1264.
22. REVESZ L, DIPADOVA FE, BUHL T et al.: SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38 MAP kinase inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:2109-2112.
23. DOMBROSKI MA, LETAVIC MA, MCCLURE KF et al.: Benzimidazolone p38 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:919-923.
24. MCINTYRE CJ, PONTICELLO GS, LIVERTON NJ et al.: Pyridazine based inhibitors of p38 MAPK. Bioorg. Med. Chem. Lett. (2002) 12:689-692.
25. RUPERT KC, HENRY JR, DODD JH et al.: Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. (2003) 13:347-350.
26. LAUFERSWEILER MJ, BRUGEL TA, CLARK MP et al.: The development of novel inhibitors of tumor necrosis factor-α (TNF-α) production based on substituted [5,5]-bicyclic pyrazolones. Bioorg. Med. Chem. Lett. (2004) 14:4267-4272.
27. TOWNES JA, GOLEBIOWSKI A, CLARK MP et al.: The development of new bicyclic pyrazole-based cytokine synthesis inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:4945-4948.
28. GODL K, WISSING J, KURTENBACH A et al.: An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. USA (2003) 100:15434-15439.
29. OTTOSEN ER, SORENSEN MD, BJORKLING F et al.: Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J. Med. Chem. (2003) 46:5651-5662.
30. LEO PHARMACEUTICALS: Press release (April 2002).
31. REVESZ L, BLUM E, DIPADOVA FE et al.: SAR of benzoylpyridines and benzophenones as p38 MAP kinase inhibitors with oral activity. Bioorg. Med. Chem. Lett. (2004) 14:3601-3605.
32. VERTEX PHARMACEUTICALS, INC.: Press release (September 2001).
33. VERTEX PHARMACEUTICALS, INC.: Press release (May 2003 and April 2004).
34. LIU L, STELMACH JE, NATARAJAN SR et al.: SAR of 3,4-dihydropyrido[3,2-d]pyrimidone p38 inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:3979-3982.
35. FITZGERALD CE, PATEL SB, BECKER JW et al.: Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struc. Biol. (2003) 10:764-769.
36. MAVUNKEL BJ, CHAKRAVARTY S, PERUMATTAM JJ et al.: Indole-based heterocyclic inhibitors of p38α MAP kinase: designing a conformationally restricted analogue. Bioorg. Med. Chem. Lett. (2003) 13:3087-3090.
37. TONG SE, DANIELS SE, CHANG S et al.: SCIO 469, a novel p38α MAPK inhibitor, provides efficacy in acute post-surgical dental pain. Clin. Pharm. Ther. (2004) 75(2):3.
38. MAVUNKEL B, CHAKRAVATY S, PERUMATTAM JJ et al.: Discovery & biological evaluation of p38α MAP kinase Inhibitor SX-011. International Symposium on Advances in Synthetic, Combinatorial and Medicinal Chemistry. Moscow, Russia (May 5-8 2004).
39. Annual Press Conference 2003: Boehringer Ingelheim Company Presentation. (8 April 2003).
40. REGAN J, BREITFELDER S, CIRILLO P et al.: Pyrazole urea-base inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J. Med. Chem. (2002) 45:2994-3008.
41. CUMMING JC, McKENZIE CL, BOWDEN SG et al.: Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. (2004) 14:5389-5394.